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Abstract
Background: Phelan-McDermid syndrome (PMS) or 22q13.3 deletion syndrome is characterized by global
developmental delay, cognitive deficits, and behaviour in the autism spectrum. Knowledge about developmental and
behavioural characteristics of this rare chromosomal disorder is still limited despite a rapid growing number of diagnoses.
Our aim was to study a new and relatively large cohort to further characterize the developmental phenotype of children
with PMS.
Methods: We performed a descriptive study of children with a 22q13.3 deletion including SHANK3, aged 8 to
178 months, who were systematically (n = 34) and longitudinally (n= 29) assessed with standardized instruments: Bayley
Scales of Infant and Toddler Development, third edition; Wechsler Preschool and Primary Scale of Intelligence, third
edition; and Vineland Screener for Social and Adaptive Behavior.
Results: Maximal developmental functioning ranged from 34 to 52 months depending on the developmental domain. In
general, children performed poorest in the domain of language and best on the domain of motor (young children) or
cognitive development (older children). At the individual level, 25 % scored better for receptive and 18 % for expressive
language, whereas 22 % scored better for fine and 33 % for gross motor function. Developmental quotients were higher
in younger children and decreased with age for all developmental domains, with 38 % of the children showing no
improvement of cognitive developmental functioning. Almost all children (33/34) had significant deficits in adaptive
behaviour. Children with very small deletions, covering only the SHANK3, ACR, and RABL2B genes, had a more favourable
developmental phenotype.
Conclusions: Cognitive, motor, and especially language development were significantly impaired in all children with PMS
but also highly variable and unpredictable. In addition, deficits in adaptive behaviour further hampered their cognitive
development. Therefore, cognitive and behavioural characteristics should be evaluated and followed in each child with
PMS to adapt supportive and therapeutic strategies to individual needs. Further research evaluating the relationship
between deletion characteristics and the developmental phenotype is warranted to improve counselling of parents.
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Background
Phelan-McDermid syndrome (PMS; MIM# 606232) is
one of the more common microdeletion syndromes
(deletion 22q13.3) with hundreds of individual diagnoses
made worldwide (Phelan-McDermid Syndrome Founda-
tion, Venice, FL) since it was first reported in 1985 [1].
To our knowledge, there are at least 60 children and 30
adults currently diagnosed in the Netherlands based on
data supplied by the eight genetic centres in the
Netherlands. These numbers are likely to be underesti-
mates due to the non-specific physical features of PMS,
but the number of diagnosed individuals has rapidly in-
creased since the introduction of non-targeted micro-
array techniques in diagnostics. Children with PMS have
a global developmental delay with cognitive deficits, be-
havioural problems in the autism spectrum and mild
dysmorphic features. Some children also have congenital
kidney anomalies and neurological problems such as ab-
normal movement patterns, seizures, reduced sensitivity
to pain, and an inability to regulate sweating [2]. The
syndrome is still under-diagnosed in adults with intellec-
tual disability, who may present with deterioration in
cognitive functioning and atypical bipolar disorders with
loss of acquired skills [3–5]. The extensive cognitive and
behavioural and physical problems associated with this
disorder are a social and emotional challenge for
patients and their families.
The cause of PMS is a microdeletion of the distal q-arm
of chromosome 22, within band q13.3 [6]. The most com-
mon cause is a terminal deletion that varies in size from
100 kb to over 9 Mb. It can be the result of a pure terminal
deletion, secondary to an unbalanced translocation or due
to a ring chromosome 22 [7]. Currently, the hypothesis is
that deletion of the SHANK3 gene, located on 22q13.3, is
the major contributor to the neurological features of this
syndrome [8]. The SHANK3 protein is an important scaf-
fold in the post-synapses of neurons in areas of the brain
that are important for learning and cognition as well as for
communication [9–11]. Individuals with an intragenic dele-
tion or a mutation of SHANK3 share the features of intel-
lectual disability and autistic behaviour [12–14], making
22q13.3 deletion syndrome a widely studied model for aut-
ism. However, other genes probably contribute to the
phenotype of PMS because patients with interstitial dele-
tions not involving SHANK3 share similar clinical features
[15, 16]. In terminal deletions with a size above 6.7 Mb, the
PARVB gene and the nearby upstream-located SULT4A1
gene have been suggested to contribute to phenotype sever-
ity [16]. Genotype-phenotype studies in larger populations
would contribute to a better resolved definition for PMS.
For this study, we define PMS as those patients with a ter-
minal 22q13.3 deletion including SHANK3.
Unfortunately, detailed information about develop-
mental characteristics in PMS is still limited and
incomplete. Kolevzon and colleagues provided a useful
overview of practice parameters for medical care of indi-
viduals with PMS, but cognitive and behavioural assess-
ments did not come within the scope of their paper [17].
To date, only three prospective or systematic studies
have been published in which development and autistic
behaviour are tested in a standardized manner and in a
larger sample instead of individual case reports [6, 18,
19]. These studies report a highly variable level of cogni-
tive functioning with the majority of patients presenting
with moderate to severe intellectual disability [6, 19].
The most affected developmental domain is language, al-
though receptive language is usually reported to be
stronger than expressive language. The least-affected do-
main is motor functioning, with gross motor function
being stronger than fine motor function [18, 19]. How-
ever, these few cross-sectional studies did not perform
follow-up studies. Nor did they take into account the ef-
fect of age at testing and individual deletion characteris-
tics. The age at testing is important to consider because
developmental functioning of children with intellectual
disability changes with age, with the difference compared
to typical peers increasing over time [20]. These studies
also did not report on the influence of autistic features
like a lack of communication, socialization, and adaptive
behaviour, which can prevent children from acquiring
new skills and therefore hamper their developmental po-
tential [21]. As a result, the reported level of develop-
mental functioning can be an under- or overestimation
depending on the mean age at testing and the presence
of autistic behaviour in the study sample. More detailed
information on developmental characteristics in children
with PMS is clearly necessary to assist paediatricians,
psychiatrists, and other health care professionals involved
in the care of these children. This information would con-
tribute to improved counselling of parents, identification of
specific problems, and better organization of adequate and
individualized support for individuals with PMS.
The aim of this study was to systematically and longi-
tudinally assess development in a new and relatively
large cohort of children with PMS. This descriptive
study not only focuses on different domains of develop-
ment, e.g. cognitive, language, and motor development,
but also evaluates the age at testing, deficits in adaptive
behaviour and deletion size. Moreover, we present the
first follow-up data in 29 individuals with PMS. The data
presented here contribute to and expand upon the




Participants for this descriptive study were recruited
among children with 22q13.3 deletion syndrome
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diagnosed at the Clinical Genetics department of the
University Medical Centre Groningen or referred from
other university medical centres in the Netherlands. All
diagnoses of a 22q13.3 deletion were made by molecular
techniques. Thirty children had already participated in
independent studies performed by the same project
group (protocol ID 2009/251 and 2012/329), and devel-
opmental data from these studies are used in this study.
Four children visited our expert clinic for Rare Chromo-
some Disorders in Groningen and received developmental
tests during regular clinical care. Two trained psychologists
experienced in working with children with special needs
performed developmental assessments of the children at
their home, day-care or, for four patients, at the outpatient
clinic in Groningen. Individual data were collected from pa-
tient histories obtained from parents and from clinical data
from medical files. Parents provided written informed con-
sent. The Medical Ethical Review Board of the University
Medical Center Groningen (UMCG, the Netherlands)
approved this study.
Assessment of cognitive, language, and motor
development
To assess developmental functioning, the Bayley Scales
of Infant and Toddler Development, third edition,
adapted and validated for the Dutch population (Bayley-
III-NL), were used [22]. This instrument assesses devel-
opmental functioning in the domains of cognition,
receptive and expressive communication, and fine and
gross motor development. It is applied to infants and
young children aged 1 month to 42 months but has also
been validated in older children suspected to have devel-
opmental functioning within this calendar age range
[23]. Raw scores of each Bayley-III-NL developmental
domain were converted into a mental age, or develop-
mental age-equivalent (DAE), in months. In typical chil-
dren, this DAE approximately equals their chronological
age (CA). To investigate the level of developmental func-
tioning of our participants in relation to their expected
level of developmental functioning based on their calen-
dar age, we calculated the DAE/CA ratio at time of as-
sessment. This ratio was multiplied by 100 to result in a
developmental quotient (DQ) for each domain [24–26].
Typical children have a DAE/CA ratio of approximately
1 and a DQ of 100 (range 85–115). One child in our co-
hort (individual 31) was initially assessed with the
Bayley-III-NL but obtained maximal scores. In order to
estimate the level of cognitive functioning, she was
additionally assessed with the Wechsler Preschool and
Primary Scale of Intelligence, third edition, Dutch ver-
sion (WPPSI-III-NL) [27]. The WPPSI-III-NL is an
intelligence test designed for children aged 30 to
95 months and assesses general cognitive functioning
(full scale IQ (FSIQ)), verbal functioning (verbal
intelligence quotient (VIQ)), and performal functioning
(performal intelligence quotient (PIQ)). Raw scores of
the general cognitive functioning were converted into a
DAE and used to calculate the DQ as described above.
Results of other WPPSI-III-NL domains cannot be com-
pared to Bayley-III-NL domains and will not be
described.
Developmental follow-up
Data from children, who were assessed twice with an inter-
val of at least 5 months, were used to investigate the natural
course of development: developmental growth (DG). DG is
the change in developmental age (DAE) between the first
and second assessment. To enable comparison of the differ-
ences between the two measurements (DG) among the dif-
ferent children, DG is calculated and expressed as change
in developmental age in months over a period of 6 months.
In clinical practice, an interval of at least 1 year is usually
used as the evaluation period. However, an interval of
6 months is more suitable to future therapeutic interven-
tions like our clinical trial with intranasal insulin [28]. In
addition, a test-retest effect is not expected over 6 months
in these cognitively impaired children. DG is calculated as
the ratio of change in DAE and change in CA (per month),
multiplied by six: ((DAE2 −DAE1)/(CA2 −CA1)) × 6. A
DG ≤ 0 represents no improvement, DG= 6 normal devel-
opment and DG> 6 above average development.
Assessment of adaptive behaviour
To estimate the level of functioning in adaptive behav-
iour, we used the Vineland Screener 0–6 years [29]. This
test is based on the American short version of the Vine-
land Adaptive Behavior Scales (VABS) [30]. The Vine-
land screener 0–6 years has been developed and
validated in the Netherlands for children aged 0 to
6 years and also for older children with a developmental
age corresponding to the calendar age range of the Vine-
land Screener [29, 31–33]. It uses a limited number of
items from the four domains of adaptive behaviour por-
trayed in the original Expanded Version of the VABS.
For our study, we used the domains of communicative,
social, and daily skills. To express the level of develop-
mental functioning of adaptive behaviour, raw scores of
each VABS developmental domain were converted into a
DAE in months and a DQ was calculated as described
above.
Effect of deletion size and gender
Children were divided into three groups of different de-
letion size to investigate the hypothesis that children
with very small deletions function at a higher level.
Group 1 consisted of children with a deletion smaller
than 250 kb (including only three common OMIM
genes: SHANK3, ACR, and RABL2B). This group also
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included individual 31, who was assessed with the
WPPSI-III-NL. The remaining children were divided
into groups 2 and 3, separated by a boundary at 6.7 Mb,
which is downstream of PARVB.
We also explored the relation between gender and
cognitive developmental functioning, by dividing chil-
dren based on gender.
Data analysis
The first successful measurement of each domain was
used to illustrate individual DAEs and DQs. DAEs and
DQs were plotted for each Bayley domain. To compare
mean DAEs and DQs at different ages, children were di-
vided into four age groups: 0–35.9, 36–71.9, 72–107.9,
and ≥108 months. Mean standard deviations and ranges
were calculated for deletion size, DAE, DQ, and DG.
GraphPad Prism 5 software was used for these figures
and calculations (GraphPad Software, Inc., La Jolla, CA).
Outcome cognitive DAE was modelled as a function
of chronological age using non-linear mixed models. It
was assumed that the ratio of DAE and chronological
age follows a one-parameter Michaelis-Menten curve,
i.e. DAE/CA = 1 −CA/(θ + CA). The parameter θ was
considered subject-specific to address the correlation
among repeated results of individual children. Theta
represents the chronological age at which a child drops
to a DQ of 50. A likelihood ratio test was applied to in-
vestigate whether θ depends on deletion group and
whether there is a difference between the deletion
groups. A p value <0.05 is considered significant. The
statistical analysis was done with SAS software, version
9.4 (SAS Institute Inc., Cary, NC).
Results
Characteristics of children
Characteristics of children are summarized in Table 1.
Developmental data were collected for 34 Dutch chil-
dren, 9 males and 25 females, with ages at first assess-
ment of 8.1 to 178.1 months (median 55.7, mean
68.4 months). Twenty-nine children received a second
assessment after 5.2 to 16.1 months (median 10.0, mean
9.5 months).
In 33 children, 22q13.3 deletions were diagnosed and
characterized by high-resolution array. In one child, the
diagnosis of a terminal 22q13.3 deletion was made by
fluorescent in situ hybridization (46,XX,del(22)(q13.1).-
ish del(22)(SHANK3-,GS-99 K24-)) and the exact dele-
tion size is unknown. Deletion sizes ranged from 182 kb
to 9.2 Mb (UCSC Genome Browser, hg19 reference gen-
ome, reference to last probe position 51304566).
Four children had a small deletion of 182 to 224 kb
that includes only three OMIM genes: SHANK3, ACR,
and RABL2B. Twenty-three children had a medium-
sized deletion ranging from 377 kb to 6.6 Mb, and five
children had a larger deletion ranging from 7.3 to
9.2 Mb extending beyond the PARVB gene. Three chil-
dren had an additional copy number variation (CNV) of
another chromosome (individuals 5, 16, and 28), five
children had a deletion caused by a ring chromosome 22
(individuals 19, 21, 22, 23, and 30) and one child had a
mosaic terminal deletion (individual 7). Because the ef-
fect of a mosaic deletion is unknown, results of the latter
individual were only summarized in Table 1 and
depicted in Fig. 1 and Additional file 1: Fig. S1 but ex-
cluded from further analyses and group descriptions.
Cognitive, language, and motor development
Thirty-two children were assessed with the Bayley-III-
NL and one child with the WPPSI-III-NL (individual
31). Chronological ages were corrected for prematurity
at first and second assessments (individual 1: 6.4 and
11.5 months, individual 6: 15.6 months).
There is a high variability of cognitive DAEs and DQs
within each age group (Fig. 1). Children with a very
small deletion (<250 kb) or a ring chromosome 22 (dele-
tion size 2.3–3.4 Mb) had higher DAEs and DQs com-
pared to other children within the same age group.
Children with an additional CNV did not perform worse
than other affected children within their age group. De-
velopment of cognition appeared to increasingly deviate
from normal development (Fig. 1a, dashed line) in older
children, as also indicated by a decreasing DQ with age
(Fig. 1b). In fact, mean DAEs did increase between age
groups 1 (0–35.9 months) and 2 (36–71.9 months) but
did not further increase in age groups 3 (72–
107.9 months) and 4 (≥108 months) (Table 2). The high-
est level of cognitive functioning for children assessed
with the Bayley-III in this cohort was 38 months. One
child (individual 31) was initially assessed with the
Bayley-III-NL. Her results revealed maximum DAEs on
all domains so her developmental functioning was be-
yond the developmental age range of the Bayley-III-NL.
Therefore, she was additionally assessed with the
WPPSI-III-NL. Converting her WPPSI-III-NL raw
scores to a DAE showed a cognitive DAE of 52 months
with a corresponding DQ of 44.
The developmental patterns of cognitive DAE and DQ
were similar in the domains of language and motor de-
velopment (Additional file 1: Fig. S1 and Table 2), but
individual 31 was not included because results of the
WPPSI-III-NL cannot be compared for these domains.
Language development was more affected than other do-
mains. Maximal DAE for receptive and expressive lan-
guage was 34 months, with corresponding DQs of 53
and 29, respectively.
With respect to motor development, the ability to
walk independently was acquired between 12 and
96 months of age (Table 1, n = 28, median 24 months,
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mean 29.4 ± 18.6 SD). Maximal DAEs for fine and gross
motor domains were 35 and 33 months, with corre-
sponding DQs of 55 to 51 (Table 2). However, individual
31 could not be compared on language and motor do-
mains. She had a PIQ of 55 and a VIQ of 64, suggesting
relatively higher performal and verbal functioning
compared to the other children in this cohort but lower
than the typical peers (PIQ and VIQ >85).
In general, children in our cohort performed poorest
in the domain of language development and best in the
domain of motor development (groups 1, 2, and 3) or
cognition (group 4). There were no clinical differences









Medication at 1st assessment
1 8 13 M Terminal 6.5 25 (crawling) None
2 10 16 F Terminal 2.1 12 None
3 11 22 F Terminal 1.9 19 None
4 16 27 F Terminal 7.7 36 Salbutamol (as needed)
5 17 23 F Terminal + dup 13q (2.3 Mb) 7.3 39 (walking assisted) None
6 17 n.a. F Terminal 9.2 12 (rolling over) None
7 35 n.a. M Terminala 4.4 21 Not reported
8 37 46 F Terminal 3.2 30 Valproic acid (for absence like periods)
9 37 45 M Terminal 2.1 17 None
10 39 n.a. F Terminal 182 kb 16 Not reported
11 42 48 F Terminal 587 kb 24 Macrogol and omeprazole
12 42 53 F Terminal 6.2 27 None
13 43 49 F Terminalb 6.6 20 None
14 44 55 F Terminal 7.4 76 None
15 46 62 F Terminal 6.2 25 None
16 46 57 F Terminal + del 16p (761 kb) 3.0 42 Beclometason dipropionate, salbutamole,
ipratropium bromide
17 47 57 M Terminal 182 kb 18 Risperidone and clonidine
18 64 n.a. F Terminal 183 kb 16 Macrogol
19 65 75 F Ring 22 2.3 23 None
20 72 82 F Terminal 1.6 17 None
21 83 96 M Ring 22 3.1 28 None
22 89 99 F Ring 22 3.4 31 None
23 92 101 M Ring 22 2.7 24 None
24 92 n.a. F Terminalc n.a. n.a. Not reported
25 95 109 M Terminal 6.1 43 Melatonin
26 95 105 F Terminal 6.4 96 Omeprazole, alginic acid, domperidone,
trimethoprim, melatonin
27 109 119 F Terminal 377 kb 16 Melatonin
28 112 118 F Terminal + dup 12q (5.1 Mb) 2.0 22 None
29 113 123 M Terminal 7.8 48 None
30 118 129 F Ring 22 3.4 32 None
31 119 126 F Terminal 224 kb 15 None
32 142 150 M Terminal 5.0 24 (walking assisted) Alimemazine and melatonin
33 147 157 F Terminal 3.5 32 None
34 178 189 F Terminal 5.7 19 Lamotrigine (for fever-induced convulsions)
mo months, n.a. not available, M male, F female, dup duplication, del deletion
aMosaic deletion (in 25 % of peripheral blood cells)
bMosaic of 6.6 and 6.2 Mb deletion (in 80–85 % and 15–20 % of cells, respectively)
cDiagnosis with FISH only
Zwanenburg et al. Journal of Neurodevelopmental Disorders  (2016) 8:16 Page 5 of 12
between receptive (mean DAE 12.3, DQ 24) and expres-
sive (mean DAE 11.5, DQ 24) language, nor between
fine (mean DAE 16.2, DQ 34) and gross (mean DAE
17.1, DQ 36) motor function. At the individual level,
however, 7/ 28 children (25 %) had a DAE that was at
least 3 months higher for receptive language and 5/28
(18 %) had a DAE that was at least 3 months higher for
expressive language, with maximum differences of 12
and 7 months, respectively (data not shown). Six out of
27 children (22 %) had a DAE that was at least 3 months
higher for fine motor function and 9/27 (33 %) had a
DAE that was at least 3 months higher for gross motor
function, with maximum differences of 11 and 8 months,
respectively.
Developmental follow-up
Table 3 demonstrates the mean DG for the different age
groups, i.e. the increase in developmental age in months
per 6 months per domain. The DG is highly variable in
each age group for all domains. The mean DG shows a
similar pattern to the DQ: DG is highest in the first age
group for the domains of cognition, receptive, and ex-
pressive language and fine motor functioning and de-
creases in subsequent age groups. The DG of gross
motor functioning is highest in the second age group
and then decreases.
Five of 29 children (17 %) showed a cognitive DG of 0
and six (21 %) showed a negative cognitive DG ranging
from −0.4 to −7.0 months per 6 months (data not
shown). Children with no improvement in DG belong to
age group 2 (n = 3), group 3 (n = 3) and group 4 (n = 5).
Individual 31, who was assessed with the WPPSI-III-NL,
showed a DG of 0.9. Only five children (17 %) showed a
positive cognitive DG of more than 3 months (individ-
uals 1, 5, 8, 15, and 19), and only one of them had a
positive DG in all five domains (individual 1).
Adaptive behaviour
In our study cohort of 33 children, there is a high pro-
portion of children with deficiencies in adaptive behav-
iour, as indicated by the results of the VABS. DAEs
increase most strongly between groups 1 and 2 (Table 4).
Maximal DAEs for communicative skills, social skills,
and daily skills (all for individual 31) were 51, 61, and
59 months, with a DQ of 43, 51, and 50, respectively.
Similar to cognitive functioning, we found decreasing
DQs with increasing age for all domains of adaptive be-
haviour. Twenty-nine children had a DQ < 85 in all do-
mains (individual data not shown). Normal DQs were
only observed for children from the youngest age group
(individuals 1, 2, 3, and 6).
Deletion size and gender
Figure 2 illustrates the relation between chronological
age and DAE for children of different deletion groups.
There is a significant difference between deletion groups
(p < 0.001). The mean chronological ages at which chil-
dren drop to a DQ of 50 (θ) was 73.1 months for group
1 (CI 56.6; 89.6), 26.0 months for group 2 (CI 19.9; 32.1)
and 11.5 months for group 3 (CI 0; 24.3). There is also a
significant difference between groups 1 and 2 (p < 0.001)
and between groups 2 and 3 (p = 0.044). Thus, all dele-
tion groups follow a different developmental path.
There was no clear difference between males and fe-
males with respect to mean DAE and DQ for the differ-
ent age groups (Additional file 2: Table S1). The

































































Fig. 1 Developmental age-equivalents (DAE) (a) and developmental quotients (DQs) (b) of children with 22q13.3 deletions. Data based on Bayley-III-NL
(n= 33) and WPPSI-III-NL (n= 1) results for cognition. The dashed line represents the normal relation between DAE and age in typically developing children.
Terminal deletion terminal deletion not caused by ring chromosome formation. Mosaic deletion (individual 7), additional CNV additional copy number
variation (individuals 5,16, 28), S small deletion including only SHANK3, ACR, and RABL2B (individuals 10, 17, 18, 31)
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statistical analysis correspondingly showed a p value of
0.395 (data not shown).
Discussion
Our study is a systematic and longitudinal evaluation of
development in a relatively large cohort of 34 children
with a 22q13.3 deletion (PMS), in which 33 children had
a non-mosaic SHANK3 deletion. For these 33 children,
we reported results from different developmental do-
mains. We are the first to report the influence of age at
testing and, for 29 children, cognitive developmental
growth by follow-up. In addition, we evaluated deficits
in adaptive behaviour and deletion characteristics.
In our study group of 33 children, we found a global
developmental delay in all children with maximal DAEs
of 34 to 38 months (roughly 3–4.5 years), depending on
the Bayley-III-NL developmental domain. However, one
child (individual 31) showed maximal DAEs for all
Bayley-III-NL domains and was additionally assessed
with the WPPSI-III-NL. Although Bayley-III-NL and
WPPSI-III-NL results cannot be entirely compared, both
methods assess the level of cognitive functioning. Her
DAE for cognition showed a higher level of developmen-
tal functioning with a cognitive DAE of 52 months
(WPPSI-III-NL), increasing the range of cognitive func-
tioning in our cohort. Other studies in children with
22q13.3 deletion syndrome reported similar cognitive
age-equivalents of maximally 21 to 44 months [6, 18,
19], suggesting there is a maximal level of functioning
that can be achieved in children with PMS. The severity
of this intellectual disability prevents these children from
passing through the stages of normal development. Be-
fore the age of 2 years, normal development in a typical
child is largely sensorimotor-based and autonomic.
Between the ages of 2 and 4 years, gross motor actions
develop and word production supports concrete think-
ing. Acquired basic skills are combined and refined to
more complex skills and higher order thinking. Between
Table 2 Bayley-III-NL developmental age-equivalents (DAEs) and developmental quotients (DQs) for each age group









Cognitiona Number 6 12 7 7 32
Mean DAE months (±1 SD) 5.2 (2.8) 18.9 (9.3) 16.3 (7.7) 18.1 (9.6) 15.6 (9.4)
Range DAE months 1.0–8.0 7.0–38.0 6.0–25.0 5.0–30.0 1.0–38.0
Mean DQ (±1 SD) 45 (27) 40 (17) 19 (10) 15 (9) 31 (20)
Range DQ 6–79 16–69 6–31 3–25 3–79
Receptive language Number 6 11 7 6 30
Mean DAE months (±1 SD) 4.1 (2.7) 15.5 (9.3) 14.3 (10.7) 12.4 (12.4) 12.3 (10.0)
Range DAE months 1.1–8.0 2.1–34.0 0.2–27.0 0.2–29.0 0.2–34.0
Mean DQ (±1 SD) 35 (27) 31 (16) 16 (12) 10 (9) 24 (19)
Range DQ 7–79 5–53 0–29 0–23 0–79
Expressive language Number 6 11 7 7 31
Mean DAE months (±1 SD) 5.2 (1.7) 14.8 (6.9) 11.9 (8.2) 11.2 (11.2) 11.5 (8.2)
Range DAE months 2.2–7.0 3.2–30.0 1.2–21.0 1.0–34.0 1.0–34.0
Mean DQ (±1 SD) 42 (9) 30 (12) 14 (10) 9 (9) 24 (16)
Range DQ 34–59 8–44 1–26 1–29 1–59
Fine motor functioning Number 6 11 7 6 30
Mean DAE months (±1 SD) 6.5 (2.1) 19.3 (9.8) 17.7 (8.4) 18.5 (10.9) 16.2 (9.7)
Range DAE months 4.0–9.0 7.0–35.0 8.0–27.0 6.0–31.0 4.0–35.0
Mean DQ (±1 SD) 56 (24) 40 (18) 21 (11) 15 (9) 34 (22)
Range DQ 26–89 16–71 8–33 3–25 3–89
Gross motor functioning Number 5 11 7 6 29
Mean DAE months (±1 SD) 9.0 (3.1) 19.3 (6.8) 18.7 (6.3) 17.8 (7.1) 17.1 (7.0)
Range DAE months 4.1–12.0 9.0–33.0 9.0–27.0 6.00–26.0 4.1–33.0
Mean DQ (±1 SD) 76 (24) 40 (9) 21 (8) 14 (7) 36 (24)
Range DQ 59–119 20–54 10–29 4–22 4–119
DAE developmental age-equivalent, DQ developmental quotient
aData of individual 31 were excluded from this table because WPPSI-III-NL results cannot be compared with the Bayley-III-NL. The cognitive DAE for this individual
was 52 months
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the ages of 4 and 7 years, fine motor skills become bet-
ter, followed by discovery of abstraction of ideas and re-
lations between actions [34]. In contrast, most children
with PMS seem to acquire basic skills like walking, but
subsequent extension and refinement of these skills is
generally very limited, resulting in a developmental age-
equivalent of 3 to 4.5 years in our study group.
Soorya et al. [19] reported that language was more se-
verely affected than motor development in a group of 27
individuals with PMS. They additionally reported a bet-
ter score for receptive than expressive language and a
better score for gross than fine motor function, based on
mean age-equivalents. When looking at all ages in our
cohort, children did seem to function slightly better in
receptive rather than expressive language, but overall,
we saw a slightly better fine than gross motor function.
Looking in more detail at individual levels, however,
these findings were not consistent and very variable be-
cause the extent of these differences ranges from limited
to more pronounced and because it can be directed to
either of the two subdomains of language and motor
function domains.
We also report that the intellectual disability is less
striking in younger children with 22q13.3 deletion syn-
drome than in older children, as relative developmental
functioning (DQ) decreases with increasing age. This
relative decrease in developmental functioning is known
as ‘growing into deficit’ [35] and may, in part, be ex-
plained by the fact that developmental requirements are
lower in the first few years of life when movement is
only in a one- or two-dimensional direction and lan-
guage mainly passive. In this stage, developmental differ-
ences compared to normal peers are smaller and less
apparent. This is an important observation that indicates
that by combining DQs or IQs of older and younger
children, the severity of intellectual disability of individ-
uals with PMS may be underestimated (Table 2, last col-
umn). A comparable decrease in relative functioning
with increasing age is known but not as striking, for
more common intellectual disability disorders like Down
syndrome (trisomy 21) [36] and 22q11.2 deletion syn-
drome [37]. In Down syndrome, mean IQ decreases
from approximately 50 to 35 (a 30 % decline) between 5
and 10 years of age and in 22q11.2 deletion syndrome
from 80 to 70 (a 12 % decline). In our PMS cohort, the
mean decrease in DQ of 39 in age group 2 and 19 in
and group 4 represents a decline of 50 %. This difference
might be explained by a higher level of social/adaptive
functioning in Down syndrome and of cognitive func-
tioning in 22q11.2 deletion syndrome. Individuals with
PMS have both cognitive and adaptive behaviour defi-
cits, as demonstrated by our results. The two children
with better adaptive behaviour (individuals 2 and 3)
clearly had higher DQs for cognition (79 and 73 vs. 6–
38), receptive language (79 and 55 vs. 7–25), and fine
motor function (89 and 73 vs. 23–51) than the other
children of their age group, but they also had smaller de-
letions. Interestingly, neither of them had a high DQ for
expressive language (59 and 38 vs. 27–53). The
remaining questions in our population are whether
Table 3 Bayley-III-NL developmental growth (DG) for each age group









Cognitiona Number 5 10 6 7 28
DG in mo/6 mo, mean (±1 SD) 3.5 (3.2) 1.2 (2.0) 0.7 (1.0) –0.9 (2.8) 1.0 (2.6)
Minimum–maximum 0.6–7.0 −1.9–3.9 −0.4–2.4 −7.0–1.7 −7.0–7.0
Receptive language Number 4 7 4 5 20
DG in mo/6 mo, mean (±1 SD) 2.5 (1.5) 0.3 (2.5) −0.4 (1.5) 0.1 (1.9) 0.6 (2.1)
Minimum–maximum 0.5–3.8 −2.8–3.1 −2.0–1.2 −3.0–2.2 −3.0–3.8
Expressive language Number 4 7 4 5 20
DG in mo/6 mo, mean (±1 SD) 3.3 (1.5) 0.6 (2.4) 1.3 (0.9) 1.7 (2.5) 1.5 (2.1)
Minimum–maximum 1.0–4.4 −4.4–3.1 0.0–2.0 0.0–6.0 −4.4–6.0
Fine motor functioning Number 4 8 6 5 23
DG in mo/6 mo, mean (±1 SD) 2.5 (2.5) 0.4 (3.8) 0.3 (1.2) −0.5 (1.0) 0.5 (2.6)
Minimum–maximum 0.0–5.7 −6.7–7.2 −1.2–2.1 −1.8–0.6 −6.7–7.2
Gross motor functioning Number 5 8 5 4 22
DG in mo/6 mo, mean (±1 SD) 1.4 (2.2) 2.0 (2.1) −1.1 (2.4) −1.0 (1.7) 0.7 (2.4)
Minimum–maximum −1.0–4.3 −1.0–5.1 −4.0–1.2 −2.0–1.5 −4.0–5.1
DG developmental growth, mo months
aData of individual 31 were excluded from this table because WPPSI-III-NL results cannot be compared with the Bayley-III-NL. The cognitive DG for this individual
was 0.9 months per 6 months
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deficits in cognitive functioning lead to limited adaptive
behaviour and whether problems with adaptive behav-
iour further hamper cognitive development [38], espe-
cially in the developmental phase where progress
depends on abstract and relational thinking. Both cogni-
tive deficits and adaptive behaviour have an effect on
language development, so, either way, it is likely that
children with this combination have more difficulties
reaching a certain level of developmental functioning.
Our most disconcerting observation, however, is that
11 of our 29 children show no improvement of cognitive
developmental functioning. This finding might indicate
stagnation or even regression in these children, which
support the reports of loss of skills we often receive from
parents. A possible explanation for this absence of cog-
nitive improvement in PMS might be the co-occurrence
of acute events. It has been reported that the loss of
skills in PMS is associated with infection, epilepsy, or
malignant neuroleptic syndrome [4]. Although we do
not have any data that suggests this was the case in our
cohort, we cannot fully exclude this possibility. System-
atic developmental studies with longer follow-up and
larger sample sizes in children and adults should be per-
formed to investigate whether stagnation and regression
are indeed part of the developmental phenotype in indi-
viduals with Phelan-McDermid syndrome. These studies
might also identify whether stagnation of development is
intrinsic to the SHANK3 deletion or if it can be attrib-
uted to problems in adaptive behaviour, acute events or
other factors.
Our results also show that the extent of developmental
deficiencies in children with 22q13.3 deletion syndrome
is highly variable within age groups, suggesting a contri-
bution of factors other than SHANK3 haploinsufficiency
to the developmental phenotype. Based on statistical ap-
proaches, Sarasua et al. 2013 [39] suggested a relation
between deletion size and level of phenotype severity.
We show that children with the smallest deletions (those
only including the SHANK3, ACR, and RABL2B genes)
do function at a relatively higher level (Fig. 1 and
Additional file 1: Fig. S1). Thus there might be an addi-
tive negative effect on development by one or more
Table 4 VABS developmental age-equivalents (DAEs) and developmental quotients (DQs) for each age group









Communicative skills Number 6 12 7 8 33
Mean DAE months (±1 SD) 8.3 (3.0) 16.4 (7.5) 14.4 (6.2) 18.1 (15.6) 14.9 (9.6)
Range DAE months 6–13 6–33 6–21 6–51 6–51
Mean DQ (±1 SD) 70 (28) 34 (11) 16 (8) 14 (13) 32 (25)
Range DQ 37–109 16–51 6–25 5–43 5–109
Social skills Number 6 12 7 8 33
Mean DAE months (±1 SD) 9.2 (4.5) 20.7 (8.9) 14.3 (9.4) 22.9 (19.6) 17.8 (12.6)
Range DAE months 1–14 3–39 3–26 1–61 1–61
Mean DQ (±1 SD) 72 (41) 44 (16) 16 (11) 17 (16) 37 (29)
Range DQ 16–138 7–65 3–29 1–51 1–138
Daily skills Number 6 12 7 8 33
Mean DAE months (±1 SD) 11.7 (3.2) 20.8 (9.7) 21.3 (9.6) 25.3 (15.9) 20.3 (11.3)
Range DAE months 10–18 10–39 10–35 14–59 10–59
Mean DQ (±1 SD) 99 (34) 44 (15) 24 (13) 20 (13) 44 (34)
Range DQ 59–156 24–64 11–49 9–50 9–156
Data on communicative, social skills and daily skills of the VABS
DAE developmental age-equivalent, DQ developmental quotient
Fig. 2 Relation between chronological age and cognitive
developmental age-equivalents (DAE) for children (n = 32) with
small deletions (group 1, n = 4), larger deletions (group 2, n = 23)
and deletions including PARVB and SULT4A1 genes (group 3, n= 5). There
is a significant difference between groups 1 and 2 (p < 0.001) and
between groups 2 and 3 (p = 0.044)
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genes located outside this smallest region, although it is
not yet known which additional genes contribute to the
phenotype. The child with a mosaic SHANK3 deletion
and the five children with a ring chromosome also seem
to function at a higher level within their age group (Fig. 1
and Additional file 1: Fig. S1). It is not surprising that a
mosaic deletion results in an ameliorated phenotype be-
cause not all cells contain the deletion, but even this in-
dividual has significant deficits in adaptive behaviour.
Why the children with a ring chromosome seem to
function better is not clear. It may partly be explained
by the limited deletion size of the ring chromosomes,
which are all between 2.3 and 3.4 Mb and thus represent
a smaller number of missing genes. Disciglio et al. 2014
[16] discussed the effect of haploinsufficiency of
SULT4A1 and PARVB genes on neurological features of
individuals with an interstitial 22q13.3 deletion that did
not include SHANK3. In our group, these genes are not
included in the deletions of the children with a ring
chromosome, but they are in the deletions of individuals
from our deletion group 3, who all have a terminal dele-
tion size ≥7.3 Mb. These group 3 children have lower
DAEs (Fig. 2) and cognitive DQs (data not shown).
However, at the individual level, the larger deletions in-
cluding SULT4A1 and PARVB genes do not predict the
level of cognitive functioning of children because DAEs
and DQs of children from deletion group 2 overlap with
those from deletion group 3. In addition, looking at indi-
vidual results within the age groups, the additive effect
of SULT4A1 and PARVB is inconsistent. In age groups 1
and 2, individuals with a SULT4A1 and PARVB deletion
had a lower DQ than individuals without deletion of
these genes (age group 1: individual 4 (DQ 31) and 5
(DQ 35) vs. individual 1 (DQ 48); age group 2: individual
14 (DQ 16) vs. individuals 12, 13, and 15 (DQs between
38 and 51)), but in age group 4, the individual with a de-
letion of these genes has a higher DQ (individual 29
(DQ 12) vs. individuals 32 and 34 (7 and 5)). One ex-
planation might be a progressive effect of SHANK3 hap-
loinsufficiency on intellectual functioning at older age.
This could lead to a less additive effect of the deletion of
other genes and thus a decrease of the deletion size ef-
fect at older age. However, our findings and explorative
statistical analysis concern a relative small sample size
with small subgroups and an additional effect of
SULT4A1 and PARVB cannot fully be excluded or sup-
ported by our study. Despite the significant results, we
consider these results not as a confirmation but as
stimulation for researchers to consider the effect of dele-
tion size and more specifically gene content on develop-
mental functioning. A larger study sample is needed to
prove this hypothesis.
In addition to the effect of age and deletion size, we
also compared mean cognitive DAEs and DQs between
males and females (Additional file 2: Table S1) and per-
formed an explorative statistical analysis. Although dele-
tion size was not included and subgroups are too small
to draw conclusions, we did not see a consistent differ-
ence between males and females. Analysis in larger sam-
ples could also include deletion size and more reliably
explore any differences that depend on gender.
Several limitations need to be considered in interpret-
ing our results. The number of participants in each age
group is small, and we could not obtain developmental
data on every domain from each child. There are several
reasons for these missing data. One is that the assess-
ment of children depends on their cooperation. There is
a high prevalence of behavioural problems in the autism
spectrum in individuals with PMS, such as a reduced
interest in social interactions and a short attention span
[19]. This makes it more difficult to obtain and keep
their attention during testing. In addition, we used a
screener version of the VABS. A more extensive test or a
second test to assess adaptive behaviour could comple-
ment and support our findings. However, the section of
the Bayley-III-NL questionnaire that assesses adaptive
behaviour is less specific and very time-consuming. In
consequence, we decided to only use the screener ver-
sion because this would be sufficient to indicate the level
of developmental functioning of adaptive behaviour and
limit the burden of the assessments. Another issue is
that children with PMS tend to lose acquired skills, at
least temporarily, in the course of an illness or other dis-
turbance of their wellbeing, sometimes without a clear
explanation [19]. This illustrates that one assessment of
development in these children does not always reliably
represent cognitive functioning and it is therefore rec-
ommended that several assessments be performed
longitudinally.
Conclusions
Our study shows that cognitive, motor and especially
language development are significantly impaired in all
children with 22q13.3 deletion syndrome including
SHANK3 as compared to children with more common
chromosomal disorders. These deficiencies are less strik-
ing in younger than older children, a phenomenon
known as ‘growing into deficit’. Very small 22q13.3 dele-
tions, i.e. those including only the SHANK3, ACR, and
RABL2B genes, have a more favourable developmental
phenotype. In addition, deficits in adaptive behaviour
further hamper cognitive development. No improvement
of developmental functioning is a common finding in
this population, and this is important to take into
account when evaluating development and treatment
effects. In particular, cognitive and behavioural charac-
teristics should be evaluated and followed in each child
with PMS to adapt supportive and therapeutic strategies
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to meet individual needs. Further research evaluating the
relation between deletion characteristics and the devel-
opmental phenotype is warranted to improve counsel-
ling of parents. Our results contribute to an improved
insight in the developmental phenotype of children with
PMS and hopefully support health care professionals in
counselling and therapeutic strategies.
Additional files
Additional file 1: Figure S1. Developmental age-equivalents (DAE) A,
C, E, G and developmental quotients (DQs) B, D, F, H of children with
22q13.3 deletions. Data based on Bayley-III-NL (n= 33) results for receptive
language, expressive language, fine motor function, and gross motor function.
The dashed line represents the normal relation between DAE and age
in typically developing children. Terminal deletion = terminal deletion
not caused by ring chromosome formation. Mosaic deletion (individual 7).
Additional CNV = additional copy number variation (individuals 5, 16, 28).
S = small deletion including only SHANK3, ACR, and RABL2B (individuals
10, 17, 18). (EPS 2.05 mb)
Additional file 2: Table S1. Bayley-III-NL developmental age-
equivalents (DAEs) and developmental quotients (DQs) for cognition
separated by gender. (XLS 18.0 kb)
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